Jim Cramer has cast doubt on reports of a potential $400 billion merger between AstraZeneca Plc and Bristol Myers Squibb Co., describing the discussions as a possible "fake out." The skepticism follows Financial Times reports that the two pharmaceutical giants have been in talks for months to form a combined entity valued at nearly $400 billion. While the deal would create the world’s fourth-largest drugmaker by market capitalization, significant uncertainty surrounds its viability due to regulatory hurdles and strategic alignment issues.

The proposed merger structure would likely involve both cash and shares, combining AstraZeneca’s market value of approximately $263 billion with Bristol Myers Squibb’s valuation of around $133 billion. William Blair analysts note that given the size of the companies, the deal would likely be largely stock-based, potentially resulting in Bristol Myers shareholders holding roughly one-third of the combined company. This transaction would surpass AstraZeneca’s previous record acquisition of Alexion for $39 billion in 2021.

Valuation Benchmarks and Deal Economics

Analysts are using historical pharma deals to assess the transaction's value. Matt Phipps cites the Celgene acquisition by Bristol Myers, the Allergan acquisition by AbbVie Inc., and the Wyeth acquisition by Pfizer Inc. as useful comparables, suggesting a revenue multiple range of 3.5x to 4.5x one-year forward consensus revenues. Assuming a 4x multiple on William Blair’s 2028 revenue estimate of $39.5 billion for Bristol Myers implies a take-out value of roughly $160 billion.

Patent Expirations and Regulatory Risks

A critical factor shaping the deal's outcome is the impending loss of exclusivity for key brands. Analyst Phipps notes that both companies face significant patent expirations by 2030, affecting key brands that generated about $50 billion in combined 2025 revenue. Specifically, the loss of exclusivity for Bristol Myers’ Eliquis in April 2028 is expected to weigh negatively on forward multiples ahead of additional clinical readouts with milvexian. These expirations increase the importance of operational synergies to justify the merger.

Regulatory scrutiny remains a major hurdle, particularly in the U.K., where AstraZeneca is a key player in the biopharma research and development ecosystem. A successful merger would expand AstraZeneca’s U.S. presence, raising concerns about major companies shifting focus abroad following its recent elevation of its New York listing. Both companies possess extensive oncology divisions, which could attract intense antitrust scrutiny from regulators concerned about reduced competition in cancer treatments.

What the Numbers Show

The convergence of AstraZeneca’s oncology strength with Bristol Myers Squibb’s AI-driven drug discovery initiatives suggests a strategic alignment aimed at accelerating pipeline development. However, the combined entity’s significant market share in cancer treatments may face intense regulatory review. Cramer’s assertion that "BMY needs help" reflects broader market concerns about Bristol Myers Squibb’s standalone trajectory as it enters a challenging period with accelerating revenue declines from patent expirations. AstraZeneca shares were down 7.98% at $156.10, while Bristol-Myers Squibb shares were down 0.90% at $64.72 on Monday.

Pomerantz LLP has launched an investigation into AstraZeneca PLC (NYSE: AZN) to determine if the company and its executives engaged in securities fraud or other unlawful practices. The probe follows the July 9, 2026 disclosure that the Phase-3 CARDIO-TTransform trial for Wainua, an amyloid cardiomyopathy treatment developed with Ionis Pharmaceuticals, failed to meet its primary endpoint. This negative clinical outcome triggered a sharp market reaction, raising concerns among investors about potential damages from misleading statements or omitted information.

The investigation by Pomerantz LLP expands the legal scrutiny on AstraZeneca, adding to an earlier probe initiated by Schall Law Firm on July 22, 2026. Both firms are examining whether AstraZeneca issued false or misleading statements regarding the efficacy of Wainua prior to the trial results. Investors who purchased AstraZeneca American Depositary Shares (ADS) are advised to contact Pomerantz LLP to discuss their rights and potential remedies in a class action lawsuit.

Market Impact and Trial Details

On July 9, 2026, AstraZeneca announced the failure of the late-stage Phase-3 CARDIO-TTransform trial. The news resulted in an immediate decline in the company’s stock price. On the same day, AstraZeneca’s ADS price fell $10.79 per share, representing a 5.7% drop, to close at $187.49 per ADS.

Investigation Scope

Pomerantz LLP, founded by Abraham L. Pomerantz, is a premier firm specializing in corporate, securities, and antitrust class litigation. The firm is investigating whether AstraZeneca’s officers and/or directors breached fiduciary duties or engaged in corporate misconduct related to the Wainua development pipeline. The firm has offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv.

Investors interested in joining the class action or discussing their claims can contact Danielle Peyton at Pomerantz LLP via email at dpeyton@pomlaw.com or by phone at 646-581-9980, ext. 7980. The firm emphasizes that prior results do not guarantee similar outcomes in legal proceedings.